Clinical trials: CTLA4 Haploinsufficiency
LRBA Deficiency, CTLA4 Haploinsufficiency
New Biomarkers for Diagnosis and Follow-up of Patients With LRBA or CTLA4 Deficiencies
Primary immune deficiencies (PID) are a group of chronic diseases characterized by recurrent infections. Apart from recurrent infections, in some of PIDs autoimmunity, allergy or malignancy could be accompanied to the diseases.
- Trial name
- NCT04377867
- Testing
- Abatacept Injection [Orencia]
- Where
- Turkey (Türkiye)
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Marmara University
CTLA4 Haploinsufficency, Chronic Cytopenia
Safety and Efficacy of Abatacept for Treating Chronic Cytopenia in Cytotoxic T-Lymphocyte Antigen 4 (CTLA4) Haploinsufficiency
Background: CTLA4 stands for cytotoxic T-lymphocyte antigen-4. It is a protein the body makes naturally to check its immune system from attacking itself.
- Trial name
- NCT03733067
- Testing
- abatacept
- Where
- United States
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
CTLA4 Haploinsufficiency
Neurologic and Immunologic Characteristics of CTLA-4 and LRBA Hereditary Deficiency
CTLA4 and LRBA deficiencies are rare genetic disorders, recently described, and associated with multiple clinical features. It ranges from recurrent infections, auto-immunity, and organ infiltration with lymphocytes.
- Trial name
- NCT05040256
- Where
- France
- Volunteers
- 20 people
- Sponsor
- University Hospital, Montpellier
Oncology, CTLA4 Haploinsufficiency
Safety and Toxicity Study of IMM27M in Patients With Advanced Solid Tumor
This is a single arm, open label, multi-center and fist in human dose escalation study, to evaluate the safety, tolerability, pharmacokinetics and anti-tumor activity in patients with advanced and metastatic solid tumor.
- Trial name
- NCT05235438
- Testing
- IMM27M
- Where
- 6 sites in China
- Volunteers
- 16 people
- Sponsor
- ImmuneOnco Biopharmaceuticals (Shanghai) Inc.